Výsledky vyhledávání - "Axel R. Hanauske"

Preclinical and Early Clinical Development of Chemotherapeutic Drugs, Mechanism-Based Agents and Biologics

Autor: Daniel D. Von Hoff, Axel-R Hanauske

Publikováno v: Holland-Frei Cancer Medicine

Overview Over the past 10 years, the approach to drug development has changed considerably. Owing to the enormous increase in insights into the molecular biology of cancer cells, a largely empirical approach has been mostly abandoned and replaced wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eeed2faac59bd5fd29af308f3f684c24
https://doi.org/10.1002/9781119000822.hfcm053

Zobrazit plný text záznamu

First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours

Autor: Klaus Mross, Jurgen Engel, Herbert Sindermann, Axel-R. Hanauske, Wolfgang E. Berdel, Clemens Unger

Publikováno v: European Journal of Cancer. 46:920-925

Aim To identify the maximum-tolerated dose (MTD) and pharmacokinetics of oral perifosine. Methods Patients with solid tumours received perifosine at dosages ranging from 100–800 mg/week. Eligibility criteria included life expectancy > 12 weeks, WHO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9825ab6ba79a9eb3ce85682fd40b6f22
https://doi.org/10.1016/j.ejca.2009.12.028

Zobrazit plný text záznamu

Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours

Autor: Jochen Fleeth, Sigrun Müller-Hagen, Frank E. Lüdtke, Jobst von Scheel, Corinna Endler, H. Depenbrock, Claus Bolling, Ute Ohnmacht, T. Graefe, Axel-R. Hanauske

Publikováno v: European Journal of Cancer. 44:2444-2452

This non-randomised Phase-I-study determined recommended dose (RD) and dose-limiting toxicities (DLTs) of four different schedules combining pemetrexed (P), gemcitabine (G) and cisplatin (C). Patients 18 years with locally advanced/metastatic cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6dd394d0d03ffdb8b145a78cd9d253b
https://doi.org/10.1016/j.ejca.2008.08.002

Zobrazit plný text záznamu

Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients

Autor: Jiirgen B. Bulitta, Ping Zhao, James Pratt, Hans Gelderblom, Richard Daifuku, Robert D. Arnold, Axel-R. Hanauske, Ahmad Awada, Dean R. Kessler, William J. Jusko, Gabriel Luciano

Publikováno v: Cancer Chemotherapy and Pharmacology. 63:1035-1048

Our objective was to build a mechanism-based pharmacodynamic model for the time course of neutropenia in cancer patients following paclitaxel treatment with a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel) and Cremophor EL-formulate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a282a24147245a2b8e10d097fa316768
https://doi.org/10.1007/s00280-008-0828-1

Zobrazit plný text záznamu

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

Autor: Robert D. Arnold, Dean R. Kessler, Hans Gelderblom, Jürgen B. Bulitta, Axel-R. Hanauske, Richard Daifuku, William J. Jusko, Gabriel Luciano, James Pratt, Ahmad Awada, Ping Zhao

Publikováno v: Cancer Chemotherapy and Pharmacology. 63:1049-1063

Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel) and Cremophor EL-formulated paclitaxel (Taxol) in human subjects, and (2) to develop a mec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f322bfd9596960af529687cdd184e6
https://doi.org/10.1007/s00280-008-0827-2

Zobrazit plný text záznamu

Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice

Autor: Volker Schirrmacher, Philipp Beckhove, Nigel J. Sweeney, Matthias Tacke, Katja Strohfeldt, Axel R. Hanauske, Clara Pampillón, Olaf Oberschmidt

Publikováno v: Anti-Cancer Drugs. 18:311-315

Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride, better known as Titanocene Y, is a newly synthesized transition metal-based anticancer drug. We studied the antitumor activity of Titanocene Y with concentrations of 2.1, 21 and 210 micromo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::965d76768c8e3750071a46ac19fd5357
https://doi.org/10.1097/cad.0b013e328010a6f7

Zobrazit plný text záznamu

Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma

Autor: S. Uktveris, K. Burk, H. Starkmann, A. Cesas, W.-H. Meyer-Moldenhauer, Feliksas Jankevičius, M. Weigel, C. Bolling, C. Lubbing, Axel-R. Hanauske, T. Graefe

Publikováno v: Investigational New Drugs. 24:521-527

To assess the efficacy, tolerability and safety of MTX-HSA (methotrexate (MTX) covalently linked to human serum albumin (HSA)) combined with cisplatin as first line therapy for advanced bladder cancer.Patients (pat) were treated with a loading dose o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b49952e51e1c1724ae080d96f484313
https://doi.org/10.1007/s10637-006-8221-6

Zobrazit plný text záznamu

Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors

Autor: Paolo Paoletti, Axel-R Hanauske, Victor J. Chen, Clet Niyikiza

Publikováno v: The Oncologist. 6:363-373

Pemetrexed disodium (ALIMTA®, “pemetrexed”) is a novel, multi-targeted antifolate that has demonstrated promising clinical activity in a wide variety of solid tumors, including non-small cell lung, breast, mesothelioma, colorectal, pancreatic, g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5694c4c28706028267ebe0efdf674e60
https://doi.org/10.1634/theoncologist.6-4-363

Zobrazit plný text záznamu

Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin

Autor: Herlinde Dumez, J. Blatter, A. van Oosterom, Axel-R. Hanauske, R. D. Johnson, R. Thödtmann, H. Depenbrock

Publikováno v: Journal of Clinical Oncology. 17:3009-3016

PURPOSE: Multitargeted antifolate (MTA; LY231514) has broad preclinical antitumor activity and inhibits a variety of intracellular enzymes involved in the folate pathways. This study was designed to (1) determine the maximum-tolerated dose (MTD), dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5867a8619fc910eeb592d22a4bf88da
https://doi.org/10.1200/jco.1999.17.10.3009

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání